Sign inJoin waitlistJoin the waitlist

Ahmed Obeidat

Program Director, Neuroimmunology Fellowship · Medical College of Wisconsin Affiliated Hospitals, Inc

Credentials: · · · · ·

History

Neuroimmunology Fellowship · Medical College of Wisconsin Affiliated Hospitals, Inc
Present
Medical College of Wisconsin Affiliated Hospitals, Inc
Present
Multiple Sclerosis Centers MS Professionals-in-Training Special Interest Group (MS-PiT), · Medical College of Wisconsin Affiliated Hospitals, Inc
Present

University of Cincinnati
2017–2018
Neurology
University of Cincinnati
2013–2017
Doctor of Medicine - Jordan University of Science and Technology - Irbid
JORDAN UNIV OF SCIENCE & TECHNOLOGY, FACULTY OF MEDICINE, IRBID
2004–2008

Research

Telemedicine in Neurological Disorders: Opportunities and Challenges
Review · Telemedicine Journal and e-Health · 2019 · 101 citations
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis
Review · Multiple Sclerosis and Related Disorders · 2021 · Last of 3 authors · Corresponding · 61 citations
Identification and management of subclinical disease activity in early multiple sclerosis: a review
Review · Journal of Neurology · 2024 · Last of 4 authors · 28 citations

Erin Longbrake
5 papers
Le Hua
5 papers
Mokshal Porwal
5 papers · 2 as a resident
Sam Hooshmand
5 papers · 2 as a fellow
Abrahim Razzak
3 papers
Aram Zabeti
3 papers
Hesham Abboud
3 papers
Nancy Sicotte
3 papers
Will Meador
3 papers
AS
Adnan Subei
2 papers
Allison Block
2 papers · 2 as a resident
Buse Sengul
2 papers

Clinical trials

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Site PI · Recruiting
SetPoint Medical Corporation
2026–2030
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2025–2031
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Site PI · Recruiting · Phase 3
National Institute of Allergy and Infectious Diseases (NIAID)
2020–2029